The development of interferon-based gene therapy for BCG unresponsive bladder cancer

from bench to bedside

Jonathan J. Duplisea, Sharada Mokkapati, Devin Plote, Kimberly S. Schluns, David McConkey, Seppo Yla-Herttuala, Nigel R. Parker, Colin P. Dinney

Research output: Contribution to journalArticle

Abstract

Background and Purpose: BCG unresponsive bladder cancer is an inherently resistant disease state for which the preferred treatment is radical cystectomy. To date, no effective intravesical therapies exist for patients who possess these resistant tumors. For this reason, many research groups are actively investigating/testing novel therapeutic agents to aid in bladder preservation for this patient population. This review article describes our 15-year experience developing and testing IFN-based gene therapy. Methods: A comprehensive review was performed of all studies pertaining to IFN-based gene therapy for non-muscle invasive bladder cancer from 2003 to 2018. Results and Conclusions: Over the past two decades, gene therapy has evolved into a powerful tool in our fight against cancer. After overcoming the initial barriers associated with gene delivery to the bladder, we have made significant strides forward in developing this novel therapeutic strategy for the treatment of this inherently resistant disease state. Our results to date are very encouraging; however, much work lies ahead to better understand and optimize this novel approach for treating non-muscle invasive bladder.

Original languageEnglish (US)
JournalWorld Journal of Urology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Mycobacterium bovis
Urinary Bladder Neoplasms
Genetic Therapy
Interferons
Urinary Bladder
Therapeutics
Cystectomy
Neoplasms
Research
Population
Genes

Keywords

  • BCG unresponsive bladder cancer
  • Gene therapy
  • Instiladrin
  • Interferon-α

ASJC Scopus subject areas

  • Urology

Cite this

The development of interferon-based gene therapy for BCG unresponsive bladder cancer : from bench to bedside. / Duplisea, Jonathan J.; Mokkapati, Sharada; Plote, Devin; Schluns, Kimberly S.; McConkey, David; Yla-Herttuala, Seppo; Parker, Nigel R.; Dinney, Colin P.

In: World Journal of Urology, 01.01.2018.

Research output: Contribution to journalArticle

Duplisea, Jonathan J. ; Mokkapati, Sharada ; Plote, Devin ; Schluns, Kimberly S. ; McConkey, David ; Yla-Herttuala, Seppo ; Parker, Nigel R. ; Dinney, Colin P. / The development of interferon-based gene therapy for BCG unresponsive bladder cancer : from bench to bedside. In: World Journal of Urology. 2018.
@article{2bd165de162142bd8e04240511ad2111,
title = "The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside",
abstract = "Background and Purpose: BCG unresponsive bladder cancer is an inherently resistant disease state for which the preferred treatment is radical cystectomy. To date, no effective intravesical therapies exist for patients who possess these resistant tumors. For this reason, many research groups are actively investigating/testing novel therapeutic agents to aid in bladder preservation for this patient population. This review article describes our 15-year experience developing and testing IFN-based gene therapy. Methods: A comprehensive review was performed of all studies pertaining to IFN-based gene therapy for non-muscle invasive bladder cancer from 2003 to 2018. Results and Conclusions: Over the past two decades, gene therapy has evolved into a powerful tool in our fight against cancer. After overcoming the initial barriers associated with gene delivery to the bladder, we have made significant strides forward in developing this novel therapeutic strategy for the treatment of this inherently resistant disease state. Our results to date are very encouraging; however, much work lies ahead to better understand and optimize this novel approach for treating non-muscle invasive bladder.",
keywords = "BCG unresponsive bladder cancer, Gene therapy, Instiladrin, Interferon-α",
author = "Duplisea, {Jonathan J.} and Sharada Mokkapati and Devin Plote and Schluns, {Kimberly S.} and David McConkey and Seppo Yla-Herttuala and Parker, {Nigel R.} and Dinney, {Colin P.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00345-018-2553-7",
language = "English (US)",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - The development of interferon-based gene therapy for BCG unresponsive bladder cancer

T2 - from bench to bedside

AU - Duplisea, Jonathan J.

AU - Mokkapati, Sharada

AU - Plote, Devin

AU - Schluns, Kimberly S.

AU - McConkey, David

AU - Yla-Herttuala, Seppo

AU - Parker, Nigel R.

AU - Dinney, Colin P.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background and Purpose: BCG unresponsive bladder cancer is an inherently resistant disease state for which the preferred treatment is radical cystectomy. To date, no effective intravesical therapies exist for patients who possess these resistant tumors. For this reason, many research groups are actively investigating/testing novel therapeutic agents to aid in bladder preservation for this patient population. This review article describes our 15-year experience developing and testing IFN-based gene therapy. Methods: A comprehensive review was performed of all studies pertaining to IFN-based gene therapy for non-muscle invasive bladder cancer from 2003 to 2018. Results and Conclusions: Over the past two decades, gene therapy has evolved into a powerful tool in our fight against cancer. After overcoming the initial barriers associated with gene delivery to the bladder, we have made significant strides forward in developing this novel therapeutic strategy for the treatment of this inherently resistant disease state. Our results to date are very encouraging; however, much work lies ahead to better understand and optimize this novel approach for treating non-muscle invasive bladder.

AB - Background and Purpose: BCG unresponsive bladder cancer is an inherently resistant disease state for which the preferred treatment is radical cystectomy. To date, no effective intravesical therapies exist for patients who possess these resistant tumors. For this reason, many research groups are actively investigating/testing novel therapeutic agents to aid in bladder preservation for this patient population. This review article describes our 15-year experience developing and testing IFN-based gene therapy. Methods: A comprehensive review was performed of all studies pertaining to IFN-based gene therapy for non-muscle invasive bladder cancer from 2003 to 2018. Results and Conclusions: Over the past two decades, gene therapy has evolved into a powerful tool in our fight against cancer. After overcoming the initial barriers associated with gene delivery to the bladder, we have made significant strides forward in developing this novel therapeutic strategy for the treatment of this inherently resistant disease state. Our results to date are very encouraging; however, much work lies ahead to better understand and optimize this novel approach for treating non-muscle invasive bladder.

KW - BCG unresponsive bladder cancer

KW - Gene therapy

KW - Instiladrin

KW - Interferon-α

UR - http://www.scopus.com/inward/record.url?scp=85056348344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056348344&partnerID=8YFLogxK

U2 - 10.1007/s00345-018-2553-7

DO - 10.1007/s00345-018-2553-7

M3 - Article

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

ER -